What are the ASCO guidelines for managing immune checkpoint inhibitor (ICI)–induced Evans syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ASCO Guidelines for ICI-Induced Evans Syndrome Management

For ICI-induced Evans syndrome, hold the immune checkpoint inhibitor immediately and initiate prednisone 1 mg/kg/day (range 0.5-2 mg/kg/day) orally for 4 weeks followed by a 4-6 week taper, with IVIG (1 g/kg as a one-time dose) added if rapid platelet recovery is needed. 1

Grading-Based Management Algorithm

The ASCO 2021 guideline addresses Evans syndrome within the context of immune thrombocytopenia (ITP) with concurrent hemolytic anemia (positive direct antigen test), using platelet count as the primary grading criterion 1:

Grade 1 (Platelet count 75 to <100,000/mL)

  • Continue ICI with close clinical follow-up and laboratory monitoring
  • No specific intervention required at this stage

Grade 2 (Platelet count 50 to <75,000/mL)

  • Hold ICI immediately and monitor for improvement
  • If not resolved, interrupt treatment until adverse event reverts to Grade 1
  • Prednisone 1 mg/kg/day (dosage range 0.5-2 mg/kg/day) orally for 4 weeks
  • Taper over 4-6 weeks to the lowest effective dose
  • IVIG may be added in conjunction with corticosteroids if more rapid platelet increase is required

Grade 3 (Platelet count 25,000 to <50,000/mL)

  • Same management as Grade 2
  • Mandatory hematology consultation
  • Consider dexamethasone 40 mg daily for 4 days as alternative to prednisone
  • IVIG dose: 1 g/kg as a one-time dose if used

Grade 4 (Platelet count <25,000/mL)

  • If corticosteroids and/or IVIG unsuccessful, escalate to:
    • Rituximab
    • Thrombopoietin receptor agonists
    • More potent immunosuppression
  • Consult American Society of Hematology ITP guidelines for further details 1

Required Workup and Evaluation

The guideline specifies comprehensive evaluation before initiating treatment 1:

  • History: Focus on autoimmune disease (personal and family history), lymphocyte-depleting therapy exposure (fludarabine, ATG, steroids, cytotoxic chemotherapy), viral illness history
  • Physical examination: Document spleen size
  • Laboratory testing:
    • CBC with differential, peripheral blood smear, reticulocyte count
    • Direct antigen test (Coombs test) to confirm concurrent hemolytic anemia (defining Evans syndrome)
    • Infectious disease screening: HIV, HCV, HBV, H. pylori
    • Nutritional evaluation
  • Bone marrow evaluation: Only if abnormalities in above testing require further diagnostic clarification or concern for aplastic anemia

Clinical Context and Pitfalls

Evans syndrome during ICI therapy is rare but well-documented 2, 3. Two recent case reports demonstrate that onset can occur after prolonged treatment (approximately 11 months in biliary tract cancer patients on durvalumab, and 26 months in a pembrolizumab-treated patient) 2, 3. This delayed presentation underscores the need for ongoing hematologic surveillance throughout ICI therapy, not just during initial treatment cycles.

Critical pitfall: The guideline emphasizes checking the direct antigen test specifically to identify concurrent Evans syndrome rather than isolated ITP 1. This distinction is crucial because Evans syndrome represents a more severe autoimmune phenomenon requiring the same aggressive management approach but with recognition of the dual pathology.

Both case reports confirm that corticosteroids remain the cornerstone of treatment, with gradual symptom improvement observed 2, 3. High-dose pulse corticosteroid therapy may be necessary in refractory cases 3.

ICI Rechallenge Considerations

The guideline does not provide explicit recommendations for ICI rechallenge after Evans syndrome resolution. However, for Grade 1 acquired hemophilia A (a related hematologic irAE), the guideline states to "hold ICPi and discuss resumption with patient only after taking into account the risks and benefits" 1, suggesting a cautious, individualized risk-benefit discussion is appropriate for severe hematologic toxicities.

Related Questions

In the follow‑up of myocarditis, what parameters should be assessed and is serial troponin measurement required?
What is the appropriate workup and management for a patient with suspected paraneoplastic syndrome?
As an oncologic rheumatologist planning a multicenter randomized trial of checkpoint inhibitor–related immunotoxicities, what comprehensive questionnaire (including baseline demographics, clinical data, vital signs, laboratory panels, and immune‑related adverse‑event symptom checklist) should be used for patient enrollment, and where can I access the online citations for this questionnaire?
What are the typical clinical features and presentation of inflammatory arthritis?
What is the appropriate evaluation and management of secretory diarrhea caused by a paraneoplastic syndrome?
Should a patient with acute leukemia who has a low-grade fever and worsening cough present to the emergency department?
What are the proper care and management guidelines for a Bivona tracheostomy tube?
In a zone 1 thoracic endovascular aortic repair using a through‑and‑through wire placed from the right axillary artery to the right femoral artery, should the wire tip be positioned in the ascending aorta during graft deployment, and how should the wire be managed?
When is a Bivona tracheostomy tube preferred over a standard cuffed PVC tracheostomy tube?
What are the recommended promethazine dosing guidelines for adults (including route, frequency, and maximum daily dose) for allergic reactions and nausea?
Should we obtain vaginal and cervical cultures before starting antibiotics for suspected Trichomonas vaginalis, Chlamydia trachomatis, or Neisseria gonorrhoeae infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.